Generic Name and Formulations:
Midodrine HCl 2.5mg, 5mg, 10mg; scored tabs.
Various generic manufacturers
Indications for Midodrine:
Symptomatic orthostatic hypotension.
Take during the day while upright; allow at least 4 hours between last dose and bedtime. 10mg 3 times daily at 3–4 hour intervals. Renal dysfunction: initially 2.5mg 3 times daily. Discontinue if no improvement after initial therapy.
Severe heart disease. Acute renal disease. Urinary retention. Pheochromocytoma. Thyrotoxicosis. Persistent, excessive supine hypertension.
Initial supine systolic pressure >180mmHg: not recommended. Monitor supine and sitting BP. Discontinue if supine hypertension occurs. Diabetes. Renal or hepatic impairment. Pregnancy (Cat.C). Nursing mothers.
Avoid concomitant drugs that increase BP (eg, phenylephrine, pseudoephedrine, ephedrine, dihydroergotamine, thyroid hormones, droxidopa); if unavoidable, monitor BP closely. Avoid concomitant MAO inhibitors or linezolid. Potentiated by sodium-retaining steroids (eg, fludrocortisone acetate); caution in increased intraocular pressure with fludrocortisone. Antagonized by α-antagonists (eg, prazosin, terazosin, doxazosin). Levels may be affected by renally-excreted alkaline drugs (eg, metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, quinidine). Cardiac glycosides, β-blockers, CNS drugs may cause bradycardia, AV block, arrhythmias; discontinue if bradycardia occurs.
Paresthesia, piloerection, dysuria, pruritus, supine hypertension, chills, pain, rash.
Formerly known under the brand name Proamatine.
Sign Up for Free e-newsletters
- Managing Chemo Brain in Pediatric Survivors of Childhood Cancer
- Aggressive Therapy Provides No Additional Advantage in Metastatic Prostate Cancer
- Excretion of Volatile Organic Compounds Higher in AYAs Using Vaping Products
- FDA, ASHP Actions to Prevent or Manage Chemotherapy Drug Shortages
- Breast Cancer Screening Recommendations Not Completely Reflective of Race, Age
- Various Aspects of Palliative Care Focus Associated With Different Outcomes In Cancer
- Cost vs Benefits: The Controversy Over Proton Beam Radiotherapy
- Patient Expectations at Odds With Actual Outcomes for Radiotherapy in Breast Cancer
- Patients Desire More Online Tools and Access
- Metformin Plus Ruxolitinib: A Potential Therapeutic Alternative for Myeloproliferative Neoplasms
- Sexual Quality of Life Decreased During, After Chemotherapy for Digestive Cancers
- CHEMO-SUPPORT: A Nursing Intervention to Relieve Chemotherapy Symptom Burden
- Approach and Management of Checkpoint Inhibitor-related Immune Hepatitis
- Revised AJCC8 Demonstrates Superior Tumor Classification for HNCSCC
- Oral Androgen Receptor Inhibitor Granted FDA Approval for Nonmetastatic CRPC
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|